









Relationship between Volatile Organic Compounds (VOCs) in exhaled breath determined by Proton Transfer Reaction Time of Flight Mass Spectrometry (PTR-TOF-MS), clinical characteristics and airway inflammation in COPD

<u>L. Carr¹</u>, L. Bryant², A. Yousuf¹, R. Cordell², M. Wilde², S. Siddiqui¹, P. Monks², C. *Brightling*¹ **Departments of** ¹**Infection, Immunity and Inflammation, and** ²**Chemistry, University of Leicester, UK**

Background

- Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition.
- Breathomics presents an opportunity to phenotype this heterogeneity.
- How breath volatile organic compounds (VOCs) relate to clinical features of disease, airway physiology and inflammation is uncertain.

Methods

- Single centre prospective study; moderate to severe COPD.
- 35 COPD subjects, 379 breath samples collected using Reciva (figure 1).
- Proton Transfer Reaction-Time Flight Mass Spectrometry used (PTR-MS).
- Breathomic data analysed using PLS-DA model and receiver-operator characteristic (ROC) curves generated.
- Profiles associated with spirometry, lung volumes, gas transfer, symptoms (mMRC and CAT questionnaires), sputum eosinophils (< versus ≥1%) and neutrophils (< versus ≥61%).

Results

CAT score (SE)

Sputum eosinophils % (SE)

Sputum neutrophils % (SE)

• Clinical characteristics were as shown Table 1.

Table 1: Clinical characteristics

 No distinct VOC breath profiles associated with airway physiology or symptoms.

19 (0.49)

5.13 (0.73)

73.39 (1.66)

Sputum eosinophil and neutrophil cut-offs did identify distinct profiles with a ROC area-under-the-curve (95% confidence intervals) 0.84 (0.77-0.86) and 0.80 (0.69-0.81) respectively. Figure 2 ROC curve for sputum Neutrophils. Figure 3 ROC curve for sputum eosinophils.

Age years (range) n = 80 70 (66-74) Female, n (%) 23 (28.75) 80 (100) Caucasian, n (%) Current smoker, n (%) 7 (8.75) Pack years (SD) 45.89(30.09) BMI, kg/m2 (SD) 27.74 (6.32) 55.00 (2.25) FEV1 % predicted (SE) I, n (%) 21 (26.25) Gold II, n (%) 30 (27.50) Stage III, n (%) 22 (27.50) IV, n (%) 7 (8.75) MRC score (SE) 2.6 (0.06) SGRQ score (SE) 45.60 (1.21)



Figure 1: ReCiva device

Conclusion

Machine Learning outcomes are partially able to relate VOC breath profiles to inflammation but not clinical characteristics.

Figure 2: ROC curve derived from breathome to discriminate between sputum neutrophils high vs low (AUROC = 0.7985)




Figure 3: ROC curve derived from breathome to discriminate between sputum eosinophil high vs low (AUROC = 0.8432)

